In early trading on Thursday, Eli Lilly (LLY) shares rose 1.9% after the company reported better-than-expected third-quarter results, driven by surging sales of Zepbound (tirzepatide) and Mounjaro. The pharmaceutical giant also raised its revenue and earnings per share guidance for 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.